Abstract: Disclosed are methods of detecting the likelihood of cancer recurrence. More particularly, the present invention discloses methods of identifying nucleic acid signatures that correlate with the likelihood of cancer recurrence, and methods of using such signatures.
Abstract: This invention relates generally to systems and methods for predicting the efficacy of a cancer therapy in a subject. The systems and methods of the disclosure can be used, for example, to determine a therapy indicator for use in assessing responsiveness to cancer therapy, to determine whether a subject is likely to respond to a new cancer therapy, and/or to determine whether a subject is likely to continue to respond to current cancer therapy.
Type:
Application
Filed:
November 16, 2018
Publication date:
November 26, 2020
Applicant:
GMDx Co Pty Ltd.
Inventors:
Nathan E. HALL, Jared MAMROT, Robyn A. LINDLEY
Abstract: The invention relates generally to methods for determining the likelihood that targeted somatic mutagenesis of a nucleic acid molecule by a mutagenic agent has occurred, and the likelihood that a mutagenic agent is a cause of targeted somatic mutagenesis of a nucleic acid molecule. The invention further relates to methods for diagnosing cancer in a subject and/or determining the likelihood that a subject has or will develop cancer, and methods for treating subjects diagnosed with cancer or determined to be likely to have or to develop cancer. In further aspects, the invention relates to methods for identifying motifs in nucleic acid molecules that are recognized or targeted by mutagenic agents.